"European Users of Weight Loss Drug Wegovy Face Lengthy Delays and High Costs"

Danish pharmaceutical company Novo Nordisk is set to launch its weight loss drug Wegovy in Germany, but the high costs and supply constraints may hinder its rollout. Germany's public health insurance program does not cover slimming and weight-loss medications, leaving most potential users to pay out of pocket. Wegovy is expected to retail between 170 and 300 euros per month in Germany, making it too expensive for many public health systems in Europe. The drug is also facing limited supply, which could impact its momentum in the industry. The German Obesity Society has called for public health systems to extend treatment and prevention measures, as weight-loss treatments are often only accessible to wealthy individuals.